supp.ai
Discover Supplement-Drug Interactions
Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: a year ago
Research Papers that Mention the Interaction
“In a randomized phase II trial in patients (pts) with advanced NSCLC, the vascular disrupting agent ASA404 vadimezan ) in combination with CP was found to improve several efficacy parameters including overall survival (OS).”
Randomized phase III placebo-controlled trial of carboplatin/paclitaxel (CP) with or without the vascular-disrupting agent vadimezan (ASA404) in advanced non-small cell lung cancer (NSCLC).
Help us improve supp.ai, we'd love to hear your feedback: Submit Feedback